Company Profile
ALTEOGEN Inc., a bio company focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology.
It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial. Its portfolio also includes ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology, and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer.
The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial. Its portfolio also includes Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial, and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. Founded in 2008, ALTEOGEN is headquartered in Daejeon, South Korea.